Regenerx Biopharmaceuticals Inc. Files Form 4 with SEC

Strategic Insights -

Regenerx Biopharmaceuticals Inc. has submitted a Form 4 document to the U.S. Securities and Exchange Commission (SEC) on July 2, 2015. The filing reflects a change in ownership and relationship between the company and its officers, directors, or owners of more than 10% of its equity securities. The document provides detailed information on the reporting person's affiliation with the company and their purchases or sales of equity securities.

Key Takeaways:

  • The SEC filing is a formal document submitted by publicly-traded companies, in this case, Regenerx Biopharmaceuticals Inc. (Source: NewsRx)
  • Form 4 is used to report changes in ownership and relationship between the company and its officers, directors, or owners of more than 10% of its equity securities (Source: NewsRx)
  • The SIC code for Regenerx Biopharmaceuticals Inc. is 2834, Pharmaceutical Preparations (Source: NewsRx)
  • The contact information for Regenerx Biopharmaceuticals Inc. is 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850, 301-208-9191 (Source: NewsRx)
  • The SEC file number for this filing is 0000914190-15-000265 (Source: NewsRx)
  • Our editors provided additional information about Form 4, highlighting the importance of these filings for publicly-traded companies and their stakeholders (Source: NewsRx)

Statistics:

  • 1 document was filed with this Form 4 (Source: NewsRx)
  • 1 Form 4 filing was made by Regenerx Biopharmaceuticals Inc. on July 2, 2015 (Source: NewsRx)
  • The filing contains information about the reporting person's relationship to the company and purchases or sales of equity securities (Source: NewsRx)
  • The SEC filing is a requirement for publicly-traded companies, such as Regenerx Biopharmaceuticals Inc. (Source: NewsRx)

Sources:

  • NewsRx, "Regenerx Biopharmaceuticals Inc. (Form 4) SEC Filing - 07/02/2015" (Source: NewsRx, July 20, 2015)
  • Securities and Exchange Commission (SEC), http://www.sec.gov/Archives/edgar/data/1125610/0000914190-15-000265-index.html (Source: SEC, July 2, 2015)